Literature DB >> 11311783

Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.

B Dean1, S Sundram, R Bradbury, E Scarr, D Copolov.   

Abstract

A number of studies suggested that cannabis use can cause or exacerbate psychoses and may increase the risk of developing schizophrenia. These findings suggest that changes in the cannabinoid system of the brain may be involved in the pathology of schizophrenia. To determine whether changes in the cannabinoid system were present in the brains of subjects with schizophrenia, we used in situ radioligand binding and autoradiography to measure the binding of [3H]CP-55940 to the cannabinoid-1 receptor in the dorsolateral prefrontal cortex (Brodmann's area 9), caudate-putamen and areas of the temporal lobe from schizophrenic and control subjects, some of whom had ingested cannabis close to death. There was an increase in the density of [3H]CP-55940 binding to cannabinoid-1 receptors in the dorsolateral prefrontal cortex from subjects with schizophrenia (mean+/-S.E.M.: 142+/-9.9 vs 119+/-6.6fmol/mg estimated tissue equivalents; P<0.05) that was independent of recent cannabis ingestion. There was an increase in the density of cannabinoid-1 receptors in the caudate-putamen from subjects who had recently ingested cannabis (151+/-9.0 vs 123+/-7.2fmol/mg estimated tissue equivalents; P<0.05) that was independent of diagnoses. These data indicate that there are changes in cannabinoid-1 receptors in the dorsolateral prefrontal cortex that may prove to be associated with the pathology of schizophrenia. By contrast, changes in the density of cannabinoid-1 receptors may occur in the caudate-putamen in response to cannabis ingestion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311783     DOI: 10.1016/s0306-4522(00)00552-2

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  108 in total

Review 1.  Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue.

Authors:  B Dean
Journal:  Postgrad Med J       Date:  2002-03       Impact factor: 2.401

Review 2.  Cannabis and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

3.  Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor distribution and G-protein activation in the 3D reconstructed epileptic rat brain.

Authors:  Katherine W Sayers; Peter T Nguyen; Robert E Blair; Laura J Sim-Selley; Robert J DeLorenzo
Journal:  Epilepsia       Date:  2012-04-17       Impact factor: 5.864

4.  Chronic blockade of CB(1) receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation.

Authors:  E Zamberletti; F Piscitelli; F Cadeddu; T Rubino; W Fratta; P Fadda; V Di Marzo; D Parolaro
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

5.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 6.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

7.  Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists.

Authors:  Matthew N Hill; Larissa M Froese; Anna C Morrish; Jane C Sun; Stan B Floresco
Journal:  Psychopharmacology (Berl)       Date:  2006-06-03       Impact factor: 4.530

8.  Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people.

Authors:  Cécile Henquet; Lydia Krabbendam; Janneke Spauwen; Charles Kaplan; Roselind Lieb; Hans-Ulrich Wittchen; Jim van Os
Journal:  BMJ       Date:  2004-12-01

Review 9.  Endocannabinoid system: potential novel targets for treatment of schizophrenia.

Authors:  Atsushi Saito; Michael D L Ballinger; Mikhail V Pletnikov; Dean F Wong; Atsushi Kamiya
Journal:  Neurobiol Dis       Date:  2012-12-07       Impact factor: 5.996

10.  Cannabis use and the risk of developing a psychotic disorder.

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.